Sifalimumab is a monoclonal antibody that targets the human immune system, specifically inhibiting the activity of interferon-alpha, a cytokine involved in the immune response. It is primarily developed for the treatment of autoimmune diseases, particularly systemic lupus erythematosus (SLE). As a human IgG1κ antibody, Sifalimumab is designed to modulate immune responses by binding to and neutralizing interferon-alpha, thereby reducing inflammation and autoimmunity. Its mechanism of action involves blocking the receptor interactions of interferon-alpha, which can lead to a decrease in the activation of immune cells that contribute to the pathogenesis of autoimmune disorders. Sifalimumab is administered via subcutaneous injection, and its pharmacokinetics and safety profile are evaluated through clinical trials. Common side effects may include injection site reactions, infections, and potential impacts on the immune system. Overall, Sifalimumab represents a targeted therapeutic approach in the management of autoimmune conditions, aiming to improve patient outcomes while minimizing systemic immunosuppression.

Sifalimumab

1006877-41-3: Sifalimumab is a monoclonal antibody that targets the human immune system, specifically inhibiting the activity of interferon-alpha, a cytokine involved in the immune response. It is primarily developed for the treatment of autoimmune diseases, particularly systemic lupus erythematosus (SLE). As a human IgG1κ antibody, Sifalimumab is designed to modulate immune responses by binding to and neutralizing interferon-alpha, thereby reducing inflammation and autoimmunity. Its mechanism of action involves blocking the receptor interactions of interferon-alpha, which can lead to a decrease in the activation of immune cells that contribute to the pathogenesis of autoimmune disorders. Sifalimumab is administered via subcutaneous injection, and its pharmacokinetics and safety profile are evaluated through clinical trials. Common side effects may include injection site reactions, infections, and potential impacts on the immune system. Overall, Sifalimumab represents a targeted therapeutic approach in the management of autoimmune conditions, aiming to improve patient outcomes while minimizing systemic immunosuppression.

<p>Sifalimumab (MEDI-545), a monoclonal antibody, inhibits IFNα to treat moderate-severe SLE.</p>

<p>Anti-Human IFNA1 Monoclonal Antibody</p>

CAS 1006877-41-3

Sifalimumab

Sifalimumab

Ref: TM-T76760

Sifalimumab

Ref: 3D-CLA1241